KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma
Published: 26 Jun 2020
Views: 1589
Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain
Prof Jesús San Miguel speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He discusses the KarMMa study initial results. KarMMa looks at idecabtagene vicleucel , a BCMA-targeted CAR T cell therapy, in patients with relapsed and refractory multiple myeloma.
Prof Miguel explains the very positive initial results, providing specific response data, and an outline of the toxicity profile.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Related Videos
ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma
Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eri...
15 Dec 2020
OncoAlert and ecancer weekly roundup for September 6-13, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
14 Sep 2020
MASTER trial updates: Dara-KRd induction, autologous transplantation and MRD res...
Dr Luciano Costa - O'Neal Comprehensive Cancer Center at UAB, Birmingham, USA
9 Jul 2020
Treating patients with multiple myeloma in the real world
Dr Ajai Chari and Prof Roman Hájek
26 Jun 2020
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine...
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
26 Jun 2020
ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for ...
Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
15 Jun 2020
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
CANDOR updated results: KdD versus Kd in patients with RRMM according to prior l...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
Immune checkpoint based approaches in AML and MDS
Dr Naval Daver - University of Texas MD Anderson Cancer Center, Houston, USA
8 Apr 2020
